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ABSTRACT 
Background: In patients treated at Veterans Affairs facilities, demographic 
and clinical characteristics have been found to influence the choice of atypical 
antipsychotic drugs. However, little is known about he influences on the choice 
between olanzapine and risperidone in patients with schizophrenia enrolled in 
Medicaid. 
Objective: The aim of this study was to determine whether demographic 
and/or clinical characteristics and/or medical-service utilization before treatment 
were related to the choice of olanzapine versus risperidone therapy using data 
from a Medicaid population with schizophrenia. 
Methods: The study sample was identified in the North Carolina (NC) 
Medicaid claims database. Data were included from patients aged 18 to 64 years 
who were diagnosed with schizophrenia; had initiated treatment with o!anza- 
pine or risperidone between July 1, 1998, and October 31, 2000; had not used 
atypical antipsychotics during the 6 months before the start of treatment; and 
were continuously eligible in the NC Medicaid program during the 6 months 
before the start of treatment. Multivariate logistic regression models were used 
to estimate the likelihood of the choice of olanzapine or risperidone associated 
with patients' demographic and clinical characteristics and medical-service uti- 
lization during the 6 months before the initiation of treatment. 
Results: A total of 764 patients (383 women, 381 men; mean age, 42.1 years) 
were included in the analysis: 420 were initially prescribed olanzapine and 344 
were prescribed risperidone. Men were more likely than women to be pre- 
scribed olanzapine compared with risperidone. Patients who had a hospitaliza- 
tion related to a psychiatric ondition during the pretreatment period were 
more likely to be prescribed olanzapine compared with risperidone (OR = 1.530; 
P = 0.043). Significant regional variation in the likelihood of prescribing olan- 
zapine or risperidone was found, with patients being prescribed risperidone at 
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a higher rate compared with olanzapine in 2 counties with the largest schizo- 
phrenic populations. 
Conclusions: In this study of data from patients with schizophrenia identi- 
fied in the NC Medicaid claims database, sex, a history of psychiatric-related hos- 
pitalization, and geographic residence were found to be correlated with the selec- 
tion of treatment with olanzapine versus risperidone. These findings need to be 
confirmed in large, randomized, prospective studies. (Curr Ther Res Clin Exp. 
2005;66:463-474) Copyright © 2005 Excerpta Medica, Inc. 
Key words: atypical antipsychotics, olanzapine, risperidone, schizophrenia, 
NC Medicaid. 
INTRODUCTION 
The introduction of atypical antipsychotics, including olanzapine, risperidone, 
clozapine, and quetiapine, during the 1990s greatly advanced pharmacologic 
care for patients with schizophrenia. However, atypical antipsychotics cost 
considerably more than typical antipsychotics (eg, haloperidol, chlorpro- 
mazine) and, facing increasing budget pressures, third-party payers are 
demanding a better understanding of the cost-effectiveness of competing drug 
regimens. To this end, numerous pharmacoeconomic studies have been con- 
ducted to compare the economic outcomes of atypical and typical antipsy- 
chotics. 1-13 Recently, attention has turned to comparative assessments of the 
treatment outcomes of atypical drugs, with particular focus on the 2 most fre- 
quently prescribed atypical antipsychotics--olanzapine a drisperidone) 4-22 
Previous studies have focused primarily on posttreatment cost comparisons 
based on retrospective data, mostly claims data. 23 However, despite the impor- 
tance of assessing posttreatment outcomes, it is crucial that groups of patients 
sampled from claims databases are comparable. Thus, an important part of any 
retrospective assessment is to assess how and why the patients using a partic- 
ular drug might differ in demographic and clinical characteristics and pretreat- 
ment resource utilization. Such information would enable researchers to design 
a treatment model that could control for incomparable characteristics while 
comparing treatment outcomes of olanzapine and risperidone. 
Although olanzapine and risperidone are in the same therapeutic ategory, 
they have different chemical properties and exhibit different adverse-effect 
profiles; which might influence treatment choice. For example, olanzapine treat- 
ment is associated with more weight gain compared with risperidone, which 
may influence clinicians' prescribing decisions. 24,25 In addition, as evidenced in 
the literature, 15,16 the effect of "time to market" might also play an important 
role in clinicians' prescribing behavior. For example, a relatively new drug 
might be more likely to be prescribed for severely ill and/or treatment-resistant 
patients compared with older medications in the same class. ~5,1G 
Some evidence has shown that demographic and clinical characteristics of
patients also might influence the choice of an atypical antipsychotic agent. 
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Using data from the national Veterans Affairs (VA) administrative databases, 
Leslie and Rosenheck 26 found that the disabled, older, and black patients were 
less likely to use an atypical antipsychotic compared with other patients; but 
those with comorbid psychiatric disorders or who had used inpatient psychi- 
atric services in the previous year were more likely to receive atypical antipsy- 
chotics. Using a signal-detection approach based on pharmacy records of the 
VA Palo Alto Health Care System, Yesavage t a127 found that patients' age and 
disease severity were associated with the choice of atypical antipsychotics. 
Specifically, patients aged <55 years and who had more inpatient treatment 
days during the previous year were more likely to be prescribed olanzapine 
compared with risperidone. These findings were corroborated by Ren et al, 28 
who, using the VA Health Administrative database, found that age, race, and 
marital status and some clinical characteristics were correlated with the choice 
between olanzapine and risperidone. 
Because most schizophrenic patients are enrolled in state Medicaid pro- 
grams, decision-makers and clinicians are particularly interested in the factors 
that might be associated with variations in the selection of atypical antipsy- 
chotics in these patients. Thus, the aim of this study was to determine whether 
patients' demographic and/or clinical characteristics and/or medical-service 
utilization 6 months before treatment was/were related to the choice of olanza- 
pine versus risperidone therapy in a Medicaid population with schizophrenia. 
MATERIALS AND METHODS 
Data Source 
The study sample was drawn from the North Carolina (NC) Medicaid claims 
database, 29which included files concerning Medicaid eligibility, prescription- 
drug claims, and medical-service claims. The eligibility file included patients' 
demographic characteristics (age, sex, race, and county of residence) and a his- 
tory of Medicaid eligibility. The prescription-drug claims file included National 
Drug Codes 3° for prescribed rugs, the number of days each drug was supplied, 
and the dates on which each drug was dispensed. Medical-service claims docu- 
mented detailed utilization information for each clinical procedure performed, 
the date of service of each procedure, expenditure, and diagnosis. We aggre- 
gated medical services into 4 categories: hospitalization, emergency care, outpa- 
tient visits, and long4erm care facility visits. A unique scrambled patient identi- 
fier was used as a key to link and merge the 3 files for data analysis. Access to 
patient data was provided by the NC State Medicaid Agency. We were fully com- 
pliant with Health Insurance Portability and Accountability Act regulations, 31
and institutional review board approval was not required. 
Study Design and Selection Criteria 
Data from patients enrolled in the NC Medicaid program were included in 
this study if the patients had >1 medical-service laim containing a diagnosis of 
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schizophrenia (identified by the International Classification of Diseases, Ninth 
Revision, Clinical Modification [ICD-9-CM] 32 code 295.xx); were aged 18 to 64 years 
as of July 1, 1998; initiated treatment with olanzapine or risperidone between 
July 1, 1998, and October 31, 2000; had not used an atypical antipsychoUc drug 
during the 6 months before the start of treatment; and were continuously en- 
rolled in the NC Medicaid program during the 6 months before the initiation 
of treatment. At least 2 claims for atypical antipsychotic drugs were required 
after the index date to eliminate trial use of these drugs. 
We selected olanzapine and risperidone for study for 3 reasons. First, al- 
though other atypical antipsychotics, including clozapine and quetiapine, 
were also available during the study period, only a small number of patients 
in the NC Medicaid database used clozapine or quetiapine. Second, olanza- 
pine and risperidone have similar profiles in terms of efficacy, timing of com- 
mercial availability, and use in the schizophrenic population. Third, both 
olanzapine and risperidone were preferred rugs in the formulary in the NC 
Medicaid program. 
Patients were assigned to treatment cohorts based on the drug first received. 
The date of the initial prescription for each study drug was designated as the 
index date. 
Medical-service utilization was categorized based on the principal diagnosis, 
as follows: schizophrenia conditions (ICD-9-CM code 295.xx); mental-health condi- 
tions, including major diseases (eg, bipolar disorder, major depressive disorder; 
ICD-9 codes 290-319); and all health conditions (any ICD-9 code). 
Statistical Analysis 
Demographic and clinical characteristics for patient cohorts were described 
using percentiles. The Student test was used to assess differences in continu- 
ous variables between treatment cohorts. The %2 test was used to compare cat- 
egoric variables associated with the groups of patients. 
To estimate the correlation of treatment choice with patient demographic 
and clinical characteristics and medical services utilization during the 6-month 
pretreatment period, multivariate logistic regression analyses were run for 3 
treatment choice models. The models included the same set of patient demo- 
graphic characteristics, type of schizophrenia, and comorbidities, but were 
differentiated by the use o f  medical services due to different conditions. 
Specifically, in models 1 to 3, the dummy variable of medical services utilization 
specified whether utilization was for mental-health conditions, schizophrenia 
conditions, or all health conditions, respectively. Because direct measures of 
severity of illness were not present in the database, a set of explanatory vari- 
ables (ie, type of schizophrenia; whether patients used emergency depart- 
ment, in-patient hospital and/or long-term care facility services; and whether 
patients had been treated with depot antipsychotics), were used as proxies for 
disease severity. All statistical analyses were performed using SAS version 8.2 
(SAS Institute Inc., Cary, North Carolina). 
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RESULTS 
Descriptive Statistics 
A total of 7869 patients in the NC Medicaid database had a diagnosis of schizo- 
phrenia. Of these, 764 patients (383 women, 381 men; mean age, 42.1 years) met 
the inclusion criteria and were included in the present analysis. Of these, 420 
(55.0%) and 344 (45.0%) patients were included in the olanzapine and risperi- 
done cohorts, respectively. The demographic and clinical characteristics of the 
2 cohorts are presented in Table I. The only statistically significant difference 
between the 2 cohorts was sex: the olanzapine cohort included significantly 
more men compared with the risperidone cohort (228 [54.3%] vs 153 [44.5%]; 
P -- 0.007). We observed some geographic variation across counties; risperidone 
was prescribed at a significantly higher rate compared with olanzapine in 
2 counties with the largest schizophrenic populations--Mecklenburg (7.3% vs 
3.6%; P < 0.023) and Guilford (5.5% vs 2.4%; P < 0.024). Rates of medical-service 
utilization were statistically similar in the intent-to-treat populations of the 
2 treatment cohorts. 
Logistic Regression Analysis 
Table II shows the results of the 3 treatment-choice models used in the mul- 
tivariate logistic regression analyses. After the set of observed confounding fac- 
tors were controlled for, all 3 models showed that the likelihood of selecting 
olanzapine versus risperidone was correlated with a set of patient factors--sex, 
county of residence, and whether a patient was hospitalized for a psychiatric 
condition. Men were more likely than women to receive olanzapine compared 
with risperidone. This finding was true for all 3 models, with ORs of 1.443 (P = 
0.025) in model 1, 1.441 (P < 0.027) in model 2, and 1.384 (P = 0.048) in model 3. 
Second, the finding that risperidone was prescribed at significantly higher ates 
in Mecklenburg and Guilford counties was also true across all 3 models (ORs: 
model 1, 0.442 [P < 0.021] and 0.405 [P < 0.027], respectively; model 2, 0.460 
[P< 0.028] and 0.399 [P< 0.025], respectively; and model 3, 0.451 [P< 0.023] and 
0.376 [P < 0.019], respectively). 
In terms of medical-service utilization, model 1 showed that patients who 
had had any hospitalizations related to a psychiatric condition were more likely 
to begin treatment with olanzapine compared with patients without such an 
event (OR, 1.530 [P = 0.043]). In contrast, models 2 and 3 showed no such corre- 
lation. In addition, no statistical correlations were found between treatment 
choice and any of the other variables analyzed (age, race, type of schizophrenia, 
and number of comorbidities). 
DISCUSSION 
Using multivariate logistic models, we examined the association between the 
selection of atypical antipsychotic drugs and patients' demographic and clini- 
cal characteristics, comorbidities, and pretreatment resource utilization. Our 
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Table I. Baseline demographic and clinical characteristics of the study patients.* 
Olanzapine Risperidone 
Characteristic (n = 420) (n = 344) P 
Age 
Mean (SD), y 41.4 (11.1) 42.9 (10.8) <0.057 
Group, no. (%) 
18 to <35 y 116 (27.6) 79 (23.0) <0.143 
35 to <43 y 106 (25.2) 95 (27.6) <0.459 
43 to <52 y 112 (26.7) 85 (24.7) 0.539 
52 to <65 y 86 (20.5) 85 (24.7) <0.163 
Sex, no. (%) 
Male 228 (54.3) 153 (44.5) 0.007 
Female 192 (45.7) 191 (55.5) <0.015 
Race, no. (%) 
White 196 (46.7) 145 (42.2) <0.212 
Black 179 (42.6) 162 (47.1) <0.216 
Other 45 (10.7) 37 (10.8) <0.986 
County of residence, no. (%)~ 
Gaston 25 (6.0) 14 (4.1) <0.240 
Wake 21 (5.0) 23 (6.7) <0.320 
Cumberland 16 (3.8) 15 (4.4) 0.701 
Mecklenburg 15 (3.6) 25 (7.3) <0.023 
Guilford 10 (2.4) 19 (5.5) <0.024 
Other 333 (79.3) 248 (72.1) <0.021 
Type of schizophrenia, no. (%)~, 
Undifferentiated 161 (38.3) 120 (34.9) <0.326 
Paranoid 142 (33.8) 128 (37.2) <0.329 
Schizoaffective 138 (32.9) 112 (32.6) <0.931 
Other 127 (30.2) 95 (27.6) <0.572 
No. of comorbidities, mean (SD) 3.5 (2.4) 3.7 (2.4) <0.261 
*Percentages may not total 100% due to rounding. 
~i-hese 5 counties had the largest schizophrenia populations. 
~Some patients received >1 diagnosis. 
study yielded several findings. An association was found between the choice of 
atypical drug treatment for schizophrenic patients and health care utilization. 
In particular, patients who had a psychiatric-related hospitalization were more 
likely to be given olanzapine than risperidone therapy. 
Although the 2 treatment groups were found to have different rates of hospi- 
talization for psychiatric onditions, they showed no difference in rates of hos- 
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pitalization for schizophrenia as a primary admitting diagnosis or for all other 
conditions. Among others, a compelling explanation for this pattern can be 
offered by the way our study sample was drawn. In deriving the study sample, 
one of the inclusion criteria was that patients must not have used any atypical 
antipsychotic drug during the 6 months before the study. Most patients did not, 
in fact, have a claim for a schizophrenia-related visit. On the other hand, they 
had been treated for other psychiatric illnesses. As a result, their utilization of 
health care, including hospitalization, would be recorded as services for psychi- 
atric conditions or all other disease conditions. 
We also found that olanzapine and risperidone were prescribed for men and 
women at different rates. The ORs for prescribing olanzapine for men were 
1.443, 1.441, and 1.384 in models 1, 2, and 3, respectively, suggesting male 
patients were more likely to receive olanzapine. Previous studies reported sig- 
nificant gender differences in the use of olanzapine versus risperidone, 28,33 but 
their results were not adjusted for other factors and might not reflect he true 
magnitude of this association with the gender. The gender difference could be 
explained by the differences in symptom presentation and sensitivity to weight 
gain between men and women. 25 
Finally, we found regional variation in prescribing patterns for olanzapine ver- 
sus risperidone. We observed that in 2 of the counties with the largest schizo- 
phrenic populations, risperidone was prescribed at a significantly higher ate com- 
pared with olanzapine. Factors uch as urban versus rural differences in patients' 
symptoms or physicians' practices could play a role in the choice of antipsychotic 
medication across counties. Regional variation in prescribing the 2 atypical drugs 
was found in a previous tudy using a Texas Medicaid population. 16In that study, 
several factors were proposed to explain the regional differences, including indus- 
try marketing practices, opinion leaders, and managed care policies. A regional dif- 
ference in physicians' prescribing practices was suggested as an important covari- 
ate in the prescription of olanzapine versus haloperidol. 33Regional variations in 
prescribing and in general medical practices in treating other disease states have 
been noted for some time. 34 Variations in use for a number of medical and surgical 
procedures have been a source of interest for health policy makers and insurers 
concerned about cost and outcomes. Classic studies include the observation of 
widely disparate rates for common surgical procedures, uch as tonsillectomies, 
hysterectomies, and cholecystectomies, n different communities. 34 Citrome t a135 
also found variation in depot antipsychotic utilization rates. 
Using the NC Medicaid patient population, our study suggests the existence of 
sample selection bias in the prescribing of atypical antipsychotics, evidenced by 
the fact that disease states in 1 group were different from those in the other 
group. We found differences insex, geographic region, and disease severity when 
olanzapine and risperidone were prescribed to patients with schizophrenia. 
Given that current practice offers more options than the 2 treatments 
assessed in the present study, our study had several imitations. Because this 
study was based on NC Medicaid claims databases, caution must be used in 
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extrapolating the results to other populations or disease states. In addition, our 
sample size was relatively small, particularly for the risperidone cohort. It is also 
worth noting that the ORs were not particularly high. Some epidemiologists view 
ORs <2 as possibly being attributable to undetected confounding variables, ORs 
between 2 and 3 as more likely to be accurate, and ORs >3 as substantial. Our 
findings were also limited by the time period and completeness of the data set 
available to us. We might not have included other potentially important explana- 
tory variables. For example, we did not have data on characteristics of the pre- 
scribing physicians or measures of symptoms or symptom severity. In general, 
pharmacoepidemiologic studies using claims databases are not inherently 
designed to answer important research questions and are associated with chal- 
lenges in addressing all potential confounders. Methods such as the use of 
propensity scores and instrumental variables can be used in combination with 
appropriate multivariate regression models to ensure equivalence of groups 
when conducting claims database studies of the association between drug expo- 
sure, economic osts, and health outcomes. A prospective, randomized study 
design would be an effective way to answer these questions. Nonetheless, the 
results of this study serve as a good starting point to think more critically about 
selection bias problems in further nonrandomized studies that involve a larger 
and possibly more general population, ideally with national representation, and 
that include other factors that could influence prescribing practices. 
The findings of the present study underscore the importance of controlling 
for sample selection bias in retrospective studies comparing the treatment 
effects of alternative drug regimens on cost and health outcomes. The associa- 
tion reported in this study is interesting, but the study design and low ORs limit 
the ability to consider this association as a true cause-and-effect relationship. 
CONCLUSIONS 
In this study of data from patients with schizophrenia identified in the NC 
Medicaid claims database, sex, a history of psychiatric-related hospitalization, 
and geographic residence were correlated with the selection of treatment with 
olanzapine versus risperidone. These findings need to be confirmed in large, 
randomized, prospective studies. 
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